Search | Clinical Trials Finder

Conditions: Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions: Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 85
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more

Conditions: Healthy
Interventions: E3810, Aciphex (rabeprazole), Nexium (esomeprazole); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: acetylsalicylic acid, esomeprazole magnesium, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy
Interventions: Esomeprazole, pantoprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Volunteers
Interventions: TAK-906, Esomeprazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gastroesophageal Reflux Disease
Interventions: Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Anaheim, California • Orange, California • San Diego, California + 4 more

Conditions: Gastroesophageal Reflux Disease
Interventions: esomeprazole; Drug
Lead sponsor: Southern Arizona VA Health Care System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: Nexium, Prevacid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Los Angeles, California • Oklahoma City, Oklahoma

Conditions: GERD With Erosive Esophagitis
Interventions: AZD0865; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 77
States / cities: Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more

Conditions: Chronic Pancreatitis
Interventions: Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Solid Tumors, Lymphoma
Interventions: Alisertib, Esomeprazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more

Conditions: NSAIDs, Upper GI Symptoms
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 31
States / cities: Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more

Conditions: Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions: Esomeprazole, Placebo proton pump inhibitor; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more

Conditions: Healthy Volunteers
Interventions: Brensocatib, Rifampin, Esomeprazole; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Crizotinib, Esomeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: pazopanib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Greenville, South Carolina

Conditions: Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions: Secretol, Nexium; Drug
Lead sponsor: Effexus Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Moline, Illinois

Conditions: Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions: esomeprazole magnesium (oral medication); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 39
States / cities: Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more

Conditions: Gastric Ulcer, Duodenal Ulcer
Interventions: Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more

Conditions: Eosinophilic Esophagitis
Interventions: Swallowed fluticasone, Esomeprazole; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Study of Acid Reflux in Asthma

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis